©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2022; 14(9): 1730-1738
Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1730
Published online Sep 27, 2022. doi: 10.4254/wjh.v14.i9.1730
Bile acids as drivers and biomarkers of hepatocellular carcinoma
Santo Colosimo, Jeremy W Tomlinson, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford OX3 7LE, United Kingdom
Santo Colosimo, School of Nutrition Science, University of Milan, Milan 20133, Italy
Author contributions: All authors have read and approve the final manuscript.
Conflict-of-interest statement: All the Authors have no conflict of interest related to the manuscript.
Corresponding author: Jeremy W Tomlinson, FRCP, PhD, Professor, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford OX3 7LE, United Kingdom.
Received: May 30, 2022
Peer-review started: May 30, 2022
First decision: July 13, 2022
Revised: July 18, 2022
Accepted: August 16, 2022
Article in press: August 16, 2022
Published online: September 27, 2022
Processing time: 115 Days and 10.9 Hours
Peer-review started: May 30, 2022
First decision: July 13, 2022
Revised: July 18, 2022
Accepted: August 16, 2022
Article in press: August 16, 2022
Published online: September 27, 2022
Processing time: 115 Days and 10.9 Hours
Core Tip
Core Tip: The rapidly increasing prevalence of hepatocellular carcinoma (HCC) highlights the unmet clinical need to develop and enhance early diagnostic strategies. Evidence from rodent and in vitro models suggests that bile acids may have a crucial role in the pathogenesis of HCC. Changes in circulating bile acid profiles are observed in patients with HCC. Serum and urine bile acid profiles may predict HCC risk and may have potential as a non-invasive screening tool.